Aarti Drugs Injects Rs 10 Crore into Subsidiary Pinnacle Life Science for Expansion

The latest announcement is out from Aarti Drugs Limited ( (IN:AARTIDRUGS) ).

Aarti Drugs Limited has approved an investment of up to Rs 10 crore in equity shares of its wholly owned subsidiary, Pinnacle Life Science Private Limited, via a rights issue, with shares to be allotted on or before March 20, 2026. The cash infusion, structured as a related-party transaction on an arm’s length basis, will fund Pinnacle’s expansion and capex plans as well as general corporate purposes, reinforcing the parent company’s strategic focus on its core pharmaceutical formulations business and supporting growth in international and domestic markets.

Pinnacle will issue 78,125 equity shares of Rs 10 each at a premium of Rs 1,270 per share, and Aarti Drugs’ post-allotment stake will remain at 100 percent, ensuring continued full control over the subsidiary. With Pinnacle reporting turnover of Rs 25,392.38 lakh in FY 2024-25 and operating in aligned therapeutic segments, the investment underscores Aarti Drugs’ intent to strengthen its vertically integrated pharma platform and enhance the subsidiary’s competitiveness in both regulated and emerging geographies.

More about Aarti Drugs Limited

Aarti Drugs Limited operates in the pharmaceutical sector, focusing on manufacturing active pharmaceutical ingredients, intermediates, and formulations for domestic and export markets. Its wholly owned material subsidiary, Pinnacle Life Science Private Limited, is a formulations manufacturer with a diversified portfolio across oncology, cardiovascular, anti-infective, and anti-diabetic therapies, exporting to over 30 countries while maintaining a presence in the Indian market.

Average Trading Volume: 6,973

Technical Sentiment Signal: Sell

Current Market Cap: 32.9B INR

Learn more about AARTIDRUGS stock on TipRanks’ Stock Analysis page.